论文部分内容阅读
目的探讨高渗晶体/胶体液在围手术期改善第三间隙积液的临床影响。方法对2006-08～2009-01间44例胃肠道癌根治术病人,研究组(n=22)输注高渗晶体/胶体液后续晶体液等常规治疗,对照组(n=22)仅给予常规治疗。比较两组病人的输液量、尿量、液体平衡、血浆总蛋白及白蛋白的变化。结果两组病人术中、术后第一个24h、术后第二个24h、术后第三个24h的输入液量、术前及术后第1天总蛋白、白蛋白比较差异无统计学意义(P>0.05)。术中及术后第三个24h尿量差异也无统计学意义(P>0.05)。但两组术后第一个24h和术后第二个24h的尿量差异有统计学意义(P<0.05),即研究组术后第一个24h尿量明显较对照组多,对照组术后第二个24h尿量较研究组多。结论高渗晶体/胶体液临床用药安全,在胃肠道癌根治术围手术期具有促进尿量峰值提前出现、明显改善减少第三间隙积液的作用。
Objective To investigate the clinical effect of hypertonic crystalloid / colloidal fluid on perioperative improvement of the third interstitial fluid. Methods Forty - four patients with gastrointestinal cancer underwent radical resection (n = 22) underwent routine infusion of hypertonic crystalloid / colloidal fluid followed by crystalloid solution during 2006-08 ~ 2009-01. The control group (n = 22) Give routine treatment. The infusion volume, urine volume, fluid balance, plasma total protein and albumin in two groups were compared. Results In the two groups, there was no significant difference between the first 24h after operation, the second 24h after operation and the third 24h after operation, and there was no significant difference in total protein and albumin between preoperative and postoperative day 1 Significance (P> 0.05). Urine volume was not significantly different between the third and fourth postoperative days (P> 0.05). However, the urine output of the first 24h after operation and the second 24h after operation were significantly different (P <0.05), that is, the urinary volume of the first 24h after operation in the study group was significantly higher than that in the control group 24h after the second urine volume more than the study group. Conclusions The clinical application of hypertonic crystalloid / colloidal solution is safe in clinical application. It has the effect of promoting the early peak of urine output in the perioperative period of radical operation of gastrointestinal cancer and obviously reducing the effect of reducing the third interstitial fluid.